Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA)
India
· Delayed Price · Currency is INR | Market Cap | 4.34T |
| Revenue (ttm) | 503.08B |
| Net Income (ttm) | 110.54B |
| Shares Out | 2.40B |
| EPS (ttm) | 46.11 |
| PE Ratio | 39.23 |
| Forward PE | 38.15 |
| Dividend | 13.50 (0.75%) |
| Ex-Dividend Date | Jul 12, 2024 |
| Volume | 2,513,230 |
| Open | 1,823.30 |
| Previous Close | 1,823.30 |
| Day's Range | 1,794.10 - 1,825.95 |
| 52-Week Range | 1,236.05 - 1,960.35 |
| Beta | 0.55 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 27, 2025 |
About NSE: SUNPHARMA
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and othe... [Read more]
Financial Performance
In 2023, SUNPHARMA's revenue was 484.97 billion, an increase of 10.51% compared to the previous year's 438.86 billion. Earnings were 95.76 billion, an increase of 13.01%.
Financial StatementsNews
Pharma Sector Stocks: Torrent Pharma (+0.25%) rises; Glenmark (-2.29%), Aurobindo (-2.02%) decline
The pharma sector showed mixed trends during the session as of 12:15 AM. Torrent Pharma was the only gainer, rising ₹8.45 to ₹3,336.30 (+0.25%). Sun Pharma dipped ₹4.95 to ₹1,800.50 (-0.27%), and Dr. ...
Motilal Oswal’s healthcare sector picks: Sun Pharma, IPCA, Mankind, Ajanta, and Glenmark
Motilal Oswal Financial Services has highlighted key stock recommendations in the healthcare sector, projecting strong growth potential for 2024. The focus includes prominent pharmaceutical companies ...
HSBC on Indian Pharma Sector: Strong 2025 Outlook for Cipla, Sun Pharma, and Torrent Pharma
HSBC retains a positive view on Indian pharmaceutical companies, projecting strong performance in 2025 led by peak gRevlimid sales and differentiated launches in the US. Companies under HSBC’s coverag...
Brokerage radar: Ceat, Sun Pharma, Godrej Consumer Products, NHPC, Reliance, Tata Power, Lloyd Metals and PG Electroplast in focus today
Brokerage houses have shared their latest insights and price targets for several stocks across industries. Here is a summary of the reports released today, Dec 9, 2024: Ceat Brokerage House: Investec ...
Jefferies on Sun Pharma: Reiterates buy rating with Rs 2150 target, sees 19.23% upside
Jefferies has reaffirmed its ‘Buy’ rating on Sun Pharma, setting a target price of ₹2150, reflecting a potential upside of 19.23% from the current market price of ₹1,803.35. The brokerage analyzed Sun...
Nifty 50 top gainers today on 29 November: Bharti Airtel, Sun Pharmaceutical and Cipla lead the rally
On November 29, 2024, Indian equity indices made a robust comeback, erasing losses from the previous session and closing on a high note. The Nifty 50 surged past the 24,100 mark, while the Sensex rose...
Sun Pharma market cap rises Rs 12,220 crore today
Sun Pharmaceutical Industries witnessed a 2.94% rise in its stock price today, closing at Rs 1,785.20. This surge resulted in an increase of Rs 12,220 crore in the company’s market capitalization, whi...
Pharma stocks: Sun Pharma up 1.27%, Dr. Reddy’s rises 0.82%, Cipla gains 0.53%
The pharmaceutical sector saw broad-based gains in early trade on November 29, 2024, with Cipla and Sun Pharma leading the charge. Here’s a detailed look at the top pharma stocks as of 10:34 AM: Stock...
Nifty 50 top gainers today on 12 November: Trent, Infosys and Sun Pharmaceutical lead the charge
On Tuesday, Indian equity markets closed on a negative note, with the benchmark indices BSE Sensex and NSE Nifty50 both witnessing declines of over 1%. The BSE Sensex ended at 78,675.18, shedding 820....
Sun Pharmaceutical’s market cap falls ₹16,816 crore as shares decline 3.92%
Sun Pharmaceutical Industries Limited experienced a sharp decline in its market capitalization, dropping by approximately ₹16,816 crore as its shares fell 3.92% to ₹1,785.50 on the NSE. This downturn ...
Sun Pharmaceutical shares decline nearly 5% as US court blocks LEQSELVI launch
Sun Pharmaceutical Industries faced a decline in shares after the US District Court of New Jersey issued a preliminary injunction preventing the company from launching its drug ‘LEQSELVI’ for severe a...
Nomura maintains neutral on Sun Pharma with slight downside, sets target price at Rs 1,850
Nomura has maintained a “Neutral” rating on Sun Pharmaceutical, setting a target price of ₹1,850, suggesting a slight downside from the current market price (CMP) of ₹1,860. This follows the recent de...
Stocks to watch today on November 4: InfoEdge, NCC, Apollo Hospitals, Sun Pharma and more
Here’s a roundup of stocks that are expected to be in focus on November 4: Stocks with potential positive move: InfoEdge: Naukri JobSpeak Index saw a 10% year-on-year increase in October, indicating a...
Sun Pharma profit up 28% on higher sales
India Business News: Sun Pharma reported a 28% increase in consolidated net profit for the second quarter ended September, at Rs 3,040 crore, with sales up by 9% to Rs 13,.
Sun Pharma shares rise nearly 3% post Q2 results; revenue grows 9% YoY to ₹13,291 crore, net profit jumps 27.5%
Sun Pharmaceutical Industries shares surge nearly 3% post Q2 results – Sun Pharma Q2 FY25 Results: Revenue grows 9% YoY to ₹13,291 crore, Net Profit jumps 27.5% YoY to ₹3,040 crore Sun Pharmaceutical ...
Sun Pharma Q2 FY25 Results Revenue grows 9%% YoY to ₹13,291.39 crore, Net Profit jumps 27.5% YoY to ₹3,040.1 crore
Sun Pharmaceutical Industries Limited reported robust Q2 FY25 financial results, reflecting strong year-over-year (YoY) growth in both revenue and net profit. The company continues to outperform marke...
Punjab National Bank shares surge nearly 4% ahead of Q2 results
Punjab National Bank (PNB) saw its share price rise by nearly 4% in the lead-up to its Q2 FY25 earnings announcement. As of 10:30 am, PNB shares were trading 3.29% higher at ₹98.87, reflecting investo...
Stock market update: Q2 FY25 results today for Bharti Airtel, IOC, Sun Pharma, Ambuja Cements, Adani Power, PNB, Suzlon, BHEL and more
Several major companies across sectors are set to announce their Q2 FY25 results today. Here’s a brief look at what to watch for: Bharti Airtel: Focus on ARPU growth and 5G expansion. IOC: Key metrics...
Studies Show Sun Pharma's WINLEVI® (clascoterone) Cream 1% Reduces Sebum Levels and is Suitable for Combination With Other Commonly Used Topical Acne Medications
WINLEVI poster presentations at 2024 Fall Clinical Dermatology Conference also include data affirming reduced acne severity and tolerability in patients with skin of color. MUMBAI , India and PRINCETO...
Stock Market update: Mahindra & Mahindra, Sun Pharmaceutical among Nifty 50 top losers today
The Indian benchmark equity indices, the BSE Sensex and the NSE Nifty50, both closed in the red on Wednesday. The BSE Sensex dropped 138.74 points (0.17 percent) to 80,081.98. On the other hand, the N...
Nifty Pharma hits record high, Divi’s Lab surges 5.83%, Cipla up 1.75%
he Nifty Pharma Index soared to record levels today, driven by strong performances across major pharmaceutical stocks. At 11:12 AM, Divi’s Laboratories led the rally, surging by 5.83%, followed by not...
UBS maintains Buy call on Sun Pharma, expects 28% upside in share price
UBS has maintained its ‘Buy’ rating on Sun Pharma, setting a target price of ₹2450, indicating a strong upside potential. UBS expects specialty products to contribute over 30% of the company’s profits...
Sun Pharma and Philogen enter into global licensing agreement for commercializing Fibromun
Sun Pharmaceutical Industries Limited and Philogen announced today that they have signed a global licensing agreement to commercialize Philogen’s speciality product, Fibromun. Fibromun, an innovative ...
No stocks under F&O ban today; Bandhan Bank and RBL Bank close to limits
Indian benchmark indices ended lower on September 27, with the Nifty slipping below 26,200. The BSE Midcap and Smallcap indices remained relatively flat. The top losers on the Nifty included Power Gri...
Stocks to Watch: RIL, Adani Enterprises, BEL, GAIL, Kaynes Technology, Lupin, Jubilant Pharma, Zomato and morein focus today (Sept 30, 2024)
Indian benchmark indices ended lower on September 27, with the Nifty slipping below 26,200. The BSE Midcap and Smallcap indices remained relatively flat. The top losers on the Nifty included Power Gri...